Current medical treatment for NAFLD/NASH; [Traitement médical de la stéatohépatite métabolique en 2022] - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Nutrition Clinique et Métabolisme Année : 2023

Current medical treatment for NAFLD/NASH

Current medical treatment for NAFLD/NASH; [Traitement médical de la stéatohépatite métabolique en 2022]

Résumé

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The high prevalence of NAFLD is related to rising rates of obesity and metabolic syndrome. NAFLD prognosis is most closely linked with fibrosis stage, which can be assessed using non-invasive tests. Therapeutic endpoints include NASH resolution and fibrosis improvement. This hepatic endpoint must be integrated into the overall metabolic issue. Therapeutic strategy is based on lifestyle interventions and weight loss. Indeed, weight loss of 7–10% can reverse liver fibrosis, but adherence to lifestyle changes remains a major problem in real life. There are currently no approved pharmacological treatments for NASH. However, several therapeutic agents are rapidly progressing through the different phases of clinical trials. We provide a summary of recent therapeutic options with most advanced results. © 2023 Société francophone nutrition clinique et métabolisme (SFNCM)

Mots clés

Fichier non déposé

Dates et versions

hal-04163614 , version 1 (17-07-2023)

Identifiants

Citer

O Masrour, Edouard Bardou-Jacquet. Current medical treatment for NAFLD/NASH; [Traitement médical de la stéatohépatite métabolique en 2022]. Nutrition Clinique et Métabolisme, 2023, 37 (2), pp.72-76. ⟨10.1016/j.nupar.2022.12.003⟩. ⟨hal-04163614⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More